Press release
Gossamer Bio Announces Data Presentation at the 2020 Crohn’s & Colitis Congress
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple ascending dose study of GB004 in healthy volunteers have been accepted for presentation at the 2020 Crohn’s & Colitis Congress being held January 23- 25 in Austin, Texas.\n\n\nDetails for the presentation are as follows:\n\n\nSession Type: Poster Session\nSession Title: Controlled Clinical Trials in Humans\nSession Date and Time: Thursday, January 23, 2020; 7:00- 9:00 p.m. CT\nPresentation Number: P066\nPresentation Title: GB004, A Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First-In-Human, Multiple-Dose Study in Healthy Subjects With Gut Biopsies\nPresenter Name: Barrett Levesque, MD\nLocation: Exhibit Hall 01 – Austin Convention Center\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200123005225/en/\n\nFor Investors:\nArgot Partners\nTel 212.600.1902\[email protected]\n\n\nFor Media:\nArgot Partners\nDavid Rosen\nTel 212.600.1902\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3301,"tagName":"div"}]